AR123619A2 - Método para producir y para controlar la viscosidad de una composición farmacéutica liofilizada de degarelix - Google Patents
Método para producir y para controlar la viscosidad de una composición farmacéutica liofilizada de degarelixInfo
- Publication number
- AR123619A2 AR123619A2 ARP210102681A ARP210102681A AR123619A2 AR 123619 A2 AR123619 A2 AR 123619A2 AR P210102681 A ARP210102681 A AR P210102681A AR P210102681 A ARP210102681 A AR P210102681A AR 123619 A2 AR123619 A2 AR 123619A2
- Authority
- AR
- Argentina
- Prior art keywords
- degarelix
- lyophilized
- pharmaceutical composition
- water
- viscosity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Un método para producir una composición farmacéutica liofilizada de degarelix y método para controlar su viscosidad y producto de degarelix, en donde el producto de degarelix liofilizado, al estar reconstituido con agua para inyección en una cantidad de 20 mg/ml, presenta una viscosidad de hasta 15 mPas, y también proporciona una sustancia de droga degarelix liofilizada que muestra, ante la disolución en agua en una cantidad de 20 mg/ml, una viscosidad de hasta 3.2 mPas, y procesos para proveer esta sustancia de droga degarelix liofilizado. Reivindicación 1: Un método para producir una composición farmacéutica liofilizada de degarelix, caracterizado porque comprende las etapas de: a. Purificar el degarelix en la forma obtenida mediante síntesis péptida de fase líquida o sólida para obtener una solución de degarelix con una pureza de por lo menos 95%; b. Evaporar el solvente a una temperatura máxima de 40ºC para concentrar la solución de degarelix para obtener degarelix aglomerado, en donde la concentración de degarelix (base libre) está en el rango de 10 a 35 g/l; c. Desaglomerar el degarelix aglomerado con ácido acético, en donde la concentración final del ácido acético está en el rango de 15% a 35% v/v; y d. Liofilizar el degarelix desaglomerado de manera de proveer la composición farmacéutica liofilizada de degarelix, en donde la composición farmacéutica liofilizada de degarelix consiste de degarelix, 4.5 a 10.0% (p/p) de ácido acético, una cantidad residual de agua, e impurezas, si las hay, resultantes del proceso de producción, y que muestra, ante la disolución en agua en una cantidad de 20 mg de degarelix base libre/ml de agua conteniendo 2.5% en peso de manitol, una viscosidad de hasta 3.2 mPas. Reivindicación 11: Un método para controlar la viscosidad de un producto de droga liofilizado que comprende una composición farmacéutica liofilizada de degarelix, para obtener un valor no mayor de 15 mPas, preferentemente dentro de una escala de 2 a 12 mPas, determinado ante la reconstitución con agua para inyección en una cantidad de 20 mg de base libre de degarelix/ml, caracterizado porque comprende las etapas de: a. Proveer la composición farmacéutica liofilizada de degarelix; b. Disolver la composición farmacéutica liofilizada de degarelix en agua conteniendo manitol para proveer una mezcla de degarelix-manitol acuosa; y c. Liofilizar la mezcla de degarelix-manitol acuosa para proveer el producto de droga, en donde la composición farmacéutica liofilizada de degarelix consiste de degarelix, 4.5 a 10.0% (p/p) de ácido acético, una cantidad residual de agua, e impurezas, si las hay, resultantes del proceso de producción, y que muestra, ante la disolución en agua en una cantidad de 20 mg de degarelix base libre/ml de agua conteniendo 2.5% en peso de manitol, una viscosidad de hasta 3.2 mPas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12170454 | 2012-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123619A2 true AR123619A2 (es) | 2022-12-21 |
Family
ID=48539181
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101926A AR092840A1 (es) | 2012-06-01 | 2013-05-31 | Elaboracion de degarelix |
| ARP210102681A AR123619A2 (es) | 2012-06-01 | 2021-09-27 | Método para producir y para controlar la viscosidad de una composición farmacéutica liofilizada de degarelix |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101926A AR092840A1 (es) | 2012-06-01 | 2013-05-31 | Elaboracion de degarelix |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US9592266B2 (es) |
| EP (4) | EP2854831B1 (es) |
| JP (1) | JP6226966B2 (es) |
| KR (1) | KR102140982B1 (es) |
| CN (2) | CN107569456A (es) |
| AR (2) | AR092840A1 (es) |
| AU (1) | AU2013269523B2 (es) |
| CA (2) | CA2874927A1 (es) |
| DE (1) | DE25151068T1 (es) |
| DK (1) | DK2854831T3 (es) |
| ES (3) | ES3037257T1 (es) |
| FI (3) | FI2854831T3 (es) |
| HR (1) | HRP20241284T1 (es) |
| HU (1) | HUE068579T2 (es) |
| IL (1) | IL235856B (es) |
| JO (1) | JO3586B1 (es) |
| LT (1) | LT2854831T (es) |
| MX (1) | MX364010B (es) |
| MY (1) | MY182320A (es) |
| NZ (2) | NZ701978A (es) |
| PH (1) | PH12014502682B1 (es) |
| PL (3) | PL4512390T1 (es) |
| RS (1) | RS66065B1 (es) |
| RU (1) | RU2657444C2 (es) |
| SG (1) | SG11201407679PA (es) |
| SI (1) | SI2854831T1 (es) |
| TW (1) | TWI580443B (es) |
| WO (1) | WO2013178788A2 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI539959B (zh) | 2008-02-11 | 2016-07-01 | 菲瑞茵國際中心股份有限公司 | 治療轉移階段攝護腺癌的方法 |
| EP2854831B1 (en) * | 2012-06-01 | 2024-07-10 | Ferring B.V. | Manufacture of degarelix |
| CN107693496A (zh) * | 2017-10-23 | 2018-02-16 | 天津双硕医药科技有限公司 | 一种注射用地加瑞克冻干粉针及制备工艺 |
| EP3590526A1 (en) * | 2018-07-05 | 2020-01-08 | Antev Limited | A lyophilization process and a teverelix-tfa lyophilizate obtained thereby |
| CN111036078B (zh) * | 2018-10-14 | 2022-04-26 | 深圳市健元医药科技有限公司 | 一种GnRH拮抗剂的后处理方法 |
| CN112125956A (zh) * | 2019-06-25 | 2020-12-25 | 深圳市健元医药科技有限公司 | 一种地加瑞克的制备方法 |
| WO2021113514A1 (en) * | 2019-12-05 | 2021-06-10 | Fresenius Kabi Usa, Llc | Method for analyzing degarelix and associated products |
| CN114460179B (zh) * | 2020-11-09 | 2024-10-18 | 深圳市健翔生物制药有限公司 | 一种注射用醋酸地加瑞克体外释放度的测定方法 |
| CN114671927A (zh) * | 2020-12-24 | 2022-06-28 | 深圳翰宇药业股份有限公司 | 地加瑞克粗肽的制备方法 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| DE2862341D1 (en) | 1977-12-26 | 1983-11-24 | Ihara Chemical Ind Co | Process for producing aromatic monocarboxylic acid |
| ATE144538T1 (de) | 1991-04-25 | 1996-11-15 | Romano Deghenghi | Lhrh-antagonisten |
| DE69330107T3 (de) | 1992-02-12 | 2004-12-30 | Daikyo Gomu Seiko, Ltd. | Medizinisches Gerät |
| SI9300468A (en) | 1992-10-14 | 1994-06-30 | Hoffmann La Roche | Injectable composition for the sustained release of biologically active compounds |
| US6828415B2 (en) | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| US5506207A (en) | 1994-03-18 | 1996-04-09 | The Salk Institute For Biological Studies | GNRH antagonists XIII |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5710246A (en) | 1996-03-19 | 1998-01-20 | Abbott Laboratories | Process for intermediates for the synthesis of LHRH antagonists |
| US5860957A (en) | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
| US5925730A (en) | 1997-04-11 | 1999-07-20 | Ferring Bv | GnRH antagonists |
| US5821230A (en) | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
| US5977302A (en) | 1997-11-20 | 1999-11-02 | Ortho-Mcneil Pharmaceutical, Inc. | Liquid phase process for the preparation of GnRH peptides |
| FR2776520B1 (fr) | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
| WO2000004897A1 (en) * | 1998-07-20 | 2000-02-03 | Peptech Limited | Bioimplant formulation |
| IL155002A0 (en) | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| US20020103131A1 (en) | 2001-01-26 | 2002-08-01 | Jacobson Jill D. | Prevention of diabetes by administration of GnRH antagonists |
| GB0117057D0 (en) | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| US7214662B2 (en) | 2001-11-27 | 2007-05-08 | Zentaris Gmbh | Injectable solution of an LHRH antagonist |
| SE0104463D0 (sv) | 2001-12-29 | 2001-12-29 | Carlbiotech Ltd As | Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister |
| CN1411803A (zh) | 2002-08-29 | 2003-04-23 | 四川大学 | 制备前体脂质体的方法及其装置 |
| RS52966B (sr) * | 2002-09-27 | 2014-02-28 | Zentaris Gmbh | Oblik za terapijsku primenu aktivnih peptida sa produženim oslobađanjem aktivnog sastojka i postupak za njihovo dobijanje |
| AR042815A1 (es) | 2002-12-26 | 2005-07-06 | Alza Corp | Dispositivo de suministro de agente activo que tiene miembros compuestos |
| SG173326A1 (en) * | 2004-06-04 | 2011-08-29 | Camurus Ab | Liquid depot formulations |
| EP1674082A1 (de) | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| WO2006069779A1 (en) | 2004-12-30 | 2006-07-06 | F. Hoffmann-La Roche Ag | Preparing of peptides with excellent solubility |
| WO2007130809A2 (en) | 2006-05-06 | 2007-11-15 | Volodymyr Brodskyy | An automatic injectable drug mixing device |
| EP1891964A1 (en) | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
| EP1967202A1 (en) | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
| IL182922A0 (en) | 2007-05-02 | 2007-09-20 | Medimop Medical Projects Ltd | Automatic liquid drug reconstitution apparatus |
| NZ621174A (en) | 2008-01-15 | 2015-09-25 | Abbvie Deutschland | Powdered protein compositions and methods of making same |
| WO2009102720A1 (en) | 2008-02-11 | 2009-08-20 | Safety Syringes, Inc. | Reconstitution means for safety device |
| TWI539959B (zh) | 2008-02-11 | 2016-07-01 | 菲瑞茵國際中心股份有限公司 | 治療轉移階段攝護腺癌的方法 |
| US20090280169A1 (en) * | 2008-05-07 | 2009-11-12 | Merrion Research Iii Limited | Compositions of peptides and processes of preparation thereof |
| IT1390924B1 (it) | 2008-07-31 | 2011-10-19 | Peruffo | Metodo di frenatura di attrezzi sportivi, dispositivo di frenatura ed attrezzo sportivo comprendente tale dispositivo di frenatura |
| ES2538828T3 (es) | 2009-04-24 | 2015-06-24 | Polypeptide Laboratories A/S | Método para la fabricación de degarelix |
| US8722088B2 (en) * | 2009-05-01 | 2014-05-13 | Ferring International Center S.A. | Pharmaceutical compositions and methods for the treatment of prostate cancer |
| TW201043221A (en) | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| US20110066386A1 (en) * | 2009-09-16 | 2011-03-17 | Chien-Chong Hong | Anesthetic sensing optical microfluidic chip system |
| WO2011066386A1 (en) | 2009-11-25 | 2011-06-03 | Novetide, Ltd. | Process for production of degarelix |
| ES2385240B1 (es) * | 2010-07-26 | 2013-09-23 | Gp-Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata. |
| EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| WO2012055903A1 (en) | 2010-10-27 | 2012-05-03 | Ferring B.V. | Process for the manufacture of degarelix and its intermediates |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| CN102204889B (zh) * | 2011-05-23 | 2013-09-18 | 蚌埠丰原涂山制药有限公司 | 一种醋酸地加瑞克冻干粉针剂及其制备方法 |
| CN103841970A (zh) | 2011-07-15 | 2014-06-04 | 辉凌公司 | 其中施用匹可硫酸盐组合物的结肠镜检查定时方法 |
| CN102329373B (zh) | 2011-09-29 | 2014-10-22 | 深圳翰宇药业股份有限公司 | 地加瑞克的固相合成工艺 |
| EP2854831B1 (en) * | 2012-06-01 | 2024-07-10 | Ferring B.V. | Manufacture of degarelix |
-
2013
- 2013-05-31 EP EP13726219.2A patent/EP2854831B1/en active Active
- 2013-05-31 FI FIEP13726219.2T patent/FI2854831T3/fi active
- 2013-05-31 EP EP25151068.1A patent/EP4512390A3/en active Pending
- 2013-05-31 PL PL25151068.1T patent/PL4512390T1/pl unknown
- 2013-05-31 RS RS20241121A patent/RS66065B1/sr unknown
- 2013-05-31 ES ES25151068T patent/ES3037257T1/es active Pending
- 2013-05-31 PL PL13726219.2T patent/PL2854831T3/pl unknown
- 2013-05-31 DE DE25151068.1T patent/DE25151068T1/de active Pending
- 2013-05-31 CN CN201710709810.8A patent/CN107569456A/zh active Pending
- 2013-05-31 EP EP25151066.5A patent/EP4512389A3/en active Pending
- 2013-05-31 WO PCT/EP2013/061264 patent/WO2013178788A2/en not_active Ceased
- 2013-05-31 ES ES13726219T patent/ES2988481T3/es active Active
- 2013-05-31 DK DK13726219.2T patent/DK2854831T3/da active
- 2013-05-31 US US14/403,775 patent/US9592266B2/en active Active
- 2013-05-31 MX MX2014014662A patent/MX364010B/es active IP Right Grant
- 2013-05-31 KR KR1020147035636A patent/KR102140982B1/ko active Active
- 2013-05-31 CA CA2874927A patent/CA2874927A1/en active Pending
- 2013-05-31 HR HRP20241284TT patent/HRP20241284T1/hr unknown
- 2013-05-31 AU AU2013269523A patent/AU2013269523B2/en active Active
- 2013-05-31 SG SG11201407679PA patent/SG11201407679PA/en unknown
- 2013-05-31 EP EP24172290.9A patent/EP4385517A3/en active Pending
- 2013-05-31 RU RU2014146272A patent/RU2657444C2/ru active
- 2013-05-31 FI FIEP25151068.1T patent/FI4512390T1/fi unknown
- 2013-05-31 NZ NZ701978A patent/NZ701978A/en unknown
- 2013-05-31 AR ARP130101926A patent/AR092840A1/es not_active Application Discontinuation
- 2013-05-31 HU HUE13726219A patent/HUE068579T2/hu unknown
- 2013-05-31 CA CA3228586A patent/CA3228586A1/en active Pending
- 2013-05-31 CN CN201380028448.8A patent/CN104334182B/zh active Active
- 2013-05-31 TW TW102119333A patent/TWI580443B/zh active
- 2013-05-31 JP JP2015514527A patent/JP6226966B2/ja active Active
- 2013-05-31 NZ NZ727679A patent/NZ727679A/en unknown
- 2013-05-31 MY MYPI2014703537A patent/MY182320A/en unknown
- 2013-05-31 ES ES25151066T patent/ES3037194T1/es active Pending
- 2013-05-31 PL PL25151066.5T patent/PL4512389T1/pl unknown
- 2013-05-31 LT LTEPPCT/EP2013/061264T patent/LT2854831T/lt unknown
- 2013-05-31 FI FIEP25151066.5T patent/FI4512389T1/fi unknown
- 2013-05-31 SI SI201332090T patent/SI2854831T1/sl unknown
- 2013-06-02 JO JOP/2013/0167A patent/JO3586B1/ar active
-
2014
- 2014-11-23 IL IL235856A patent/IL235856B/en active IP Right Grant
- 2014-12-01 PH PH12014502682A patent/PH12014502682B1/en unknown
-
2017
- 2017-01-31 US US15/420,156 patent/US10172906B2/en active Active
-
2018
- 2018-12-19 US US16/224,843 patent/US10765721B2/en active Active
-
2020
- 2020-07-30 US US16/947,382 patent/US11260102B2/en active Active
-
2021
- 2021-01-21 US US17/154,690 patent/US11510962B2/en active Active
- 2021-09-27 AR ARP210102681A patent/AR123619A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123619A2 (es) | Método para producir y para controlar la viscosidad de una composición farmacéutica liofilizada de degarelix | |
| ES2910003T3 (es) | Compuestos y composiciones de cocristal iónico de litio de anión orgánico | |
| IN2012DE00337A (es) | ||
| RS54513B1 (sr) | Liofilizacija sintetičkog lipozomalnog plućnog surfaktanta | |
| CN105451728A (zh) | 羟基酪醇及其衍生物的体内吸收促进剂及其利用 | |
| MX392770B (es) | Composición farmacéutica de estabilidad mejorada. | |
| CN102247319B (zh) | 一种含有胸腺法新的药用组合物及其制备方法 | |
| CN104507467A (zh) | 含紫杉烷系活性成分的液体组合物、其制造方法及液体制剂 | |
| WO2011036676A3 (en) | Stable cocrystals of temozolomide | |
| JP6063064B2 (ja) | 安定したノカチアシン凍結乾燥製剤 | |
| WO2016195194A3 (ko) | 신규한 tlr2 길항제 | |
| WO2012041261A3 (es) | Peptidos del veneno de escorpion rhopalorus junceus y composicion farmaceutica | |
| AR093275A1 (es) | Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos | |
| RU2679614C2 (ru) | Лиофилизированные препараты бендамустина гидрохлорида | |
| RU2016105242A (ru) | Дермальная матрица и способ получения матрицы, которая имеет синергические эффекты содержания микроцастиц, которые обеспечивают заживление ткани | |
| BR112015015483A8 (pt) | forma farmacêutica monolítica para a liberação modificada de uma combinação de ingredientes ativos e processo para produção da mesma | |
| RU2017103751A (ru) | Тонкодисперсный инсулин, тонкодисперсные аналоги инсулина и спсобы их промышленного получения | |
| CN110200927A (zh) | 一种紫杉醇冻干粉制备工艺及产物 | |
| CN102949356B (zh) | 一种含有胸腺法新的冻干制剂 | |
| RU2500396C2 (ru) | Средство, обладающее кардиопротекторным действием, и способ его получения | |
| CN105287600A (zh) | 一种抗革兰阴性菌的注射用头孢西丁钠冻干粉 | |
| CN105597087B (zh) | 一种甘精胰岛素注射液及其制备方法 | |
| CN110200914A (zh) | 一种紫杉醇胶束制备工艺及产物 | |
| CN110237039A (zh) | 一种紫杉醇冻干粉制备工艺及产物 | |
| JP5170334B2 (ja) | シベレスタットナトリウム塩又はその水和物を含有する注射用製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |